CA
NZ
UK
AU
IND
US
Legislative reforms across various jurisdictions are facilitating easier access to Medical Aid in Dying for terminally ill individuals. These changes introduce specific eligibility conditions that streamline the process, allowing patients to make important end-of-life decisions more autonomously. As more states adopt similar measures, the …
This marks a critical moment for the company as it navigates a challenging financial environment, especially when compared to a healthy year-to-date performance.
The loss widened compared with the prior year, and the company fell short of consensus expectations. Net loss for the quarter amounted to $2.6 million, while unrestricted cash and marketable securities stood at $23.3 million, up from $14.9 million at the close of 2025.
Lisata Therapeutics, Inc. (NASDAQ: LSTA) has announced a significant reduction in its workforce, cutting headcount by approximately 72% as part of a cost-reduction initiative. This move is expected to incur restructuring costs of around $1.2 million. The company aims to optimize its operations and …
Merck & Co. achieved total worldwide sales of $16.6 billion for the second quarter of 2026, up 5% from the prior year, outpacing the $15.9 billion consensus expectation. The results underline Merck's effective navigation of market challenges while showcasing a resilient pipeline rife with …
Merck & Co. Inc. (NYSE: MRK) posted total worldwide sales of $16.6 billion for the second quarter ended June 30, 2026, representing a 5% increase from the prior year. This figure comfortably exceeded the consensus estimate of $16.2 billion, reinforcing the strong market demand …
This marks a significant leadership change, as Pickett previously held multiple roles within the company. His departure reflects ongoing volatility in management, with this being the company's ninth officer or director change since August 2022. This shake-up comes amid a challenging financial backdrop for …
Niagen Bioscience, Inc. (NASDAQ: NAGE) posted net sales of $29.8 million for the second quarter, including $24.2 million generated from its flagship product, Tru Niagen. This performance fulfills the consensus estimate for the previous quarter of $0.07 earnings per share, which matches the reported …
This agreement marks a significant move in the healthcare sector and demonstrates the company’s strategic growth plans.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) revealed a net loss of $32.8 million for the second quarter, a notable rise from a loss of $26.2 million during the same period last year. The company’s earnings per share of $-0.30 also surpassed the $-0.55 consensus estimate …
Please wait processing your request...